ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

BMRN BioMarin Pharmaceutical Inc

82.00
-1.80 (-2.15%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
BioMarin Pharmaceutical Inc NASDAQ:BMRN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.80 -2.15% 82.00 80.55 84.60 84.80 82.32 84.80 1,632,894 01:00:00

BioMarin to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call and Webcast on Thursday, February 21 at ...

23/01/2019 1:30pm

PR Newswire (US)


BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more BioMarin Pharmaceutical Charts.

SAN RAFAEL, Calif., Jan. 23, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 21, at 4:30 p.m. ET to discuss fourth quarter and full year 2018 financial results and provide a general business update.

BioMarin Pharmaceutical logo (PRNewsfoto/BioMarin Pharmaceutical Inc.)

Dial-in Number 
U.S. / Canada Dial-in Number: (866) 502-9859
International Dial-in Number: (574) 990-1362
Conference ID: 8265006

Replay Dial-in Number: (855) 859-2056
Replay International Dial-in Number: (404) 537-3406
Conference ID: 8265006

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.biomarin.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio consists of seven commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.biomarin.com.  

Contacts:


Investors

Media

Traci McCarty

Debra Charlesworth

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

(415) 455-7558

(415) 455-7451

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/biomarin-to-host-fourth-quarter-and-full-year-2018-financial-results-conference-call-and-webcast-on-thursday-february-21-at-430pm-et-300782577.html

SOURCE BioMarin Pharmaceutical Inc.

Copyright 2019 PR Newswire

1 Year BioMarin Pharmaceutical Chart

1 Year BioMarin Pharmaceutical Chart

1 Month BioMarin Pharmaceutical Chart

1 Month BioMarin Pharmaceutical Chart

Your Recent History

Delayed Upgrade Clock